DNA Synthesis Market

DNA Synthesis Market Overview

The global DNA synthesis market, valued at USD 1.20 billion in 2025, is projected to reach USD 1.46 billion in 2026 and USD 8.63 billion by 2035, with a 22% CAGR during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

DNA synthesis is a process of developing deoxyribonucleic acid (DNA) molecules that can be used for the production of gene therapies and various other therapeutic candidates. The growing shift towards tailored therapies to meet individual patient requirements has surged the requirement of DNA or RNA molecules for a variety of therapeutic applications. Beyond therapeutic applications, DNA molecules also play a crucial role in medical research, disease diagnosis, analytical processes, and forensic investigation. Several studies are being conducted / have been conducted to evaluate the therapeutic usage of oligonucleotides, particularly DNA, for various medical conditions. Additionally, the oligonucleotide molecules are currently being deployed in genetic disease diagnostics, such as cancer, ovarian cancer, dyslexia, psoriasis, and Parkinson's disease.

Advanced technologies such as genetic engineering, genome sequencing technology, gel electrophoresis, DNA methylation and recombinant DNA technology enable researchers to synthesize desired oligonucleotides for the development of therapies. It is interesting to note here that several DNA-based therapies have been developed by pharmaceutical companies that aid in the treatment of diseases. Driven by the increasing demand for naturally or artificially synthesized DNA, several industrial leaders have shown active interest in this field to make the process of DNA faster, more sustainable, and more precise.

It is interesting to highlight here that various DNA synthesis companies are offering technology and services to enhance the production of DNA molecules. Interestingly, active companies in this domain have developed proprietary enzymatic DNA synthesis platforms that offer greater accessibility and convenience over DNA replication methods and improve the length of DNA fragments. Given the precision and control offered by high-throughput technologies, several researchers and oligonucleotide-based drug developers prefer to outsource DNA replication and synthesis operations from third-party service providers with the required expertise. Presently, there are several active DNA synthesis companies in the market that offer DNA synthesis technologies / services. It is worth noting here that these companies are increasing their efforts to build / expand technology-based platforms to meet the growing demand for DNA synthesis. Driven by the increasing requirement for DNA across various applications and ongoing efforts of industrial leaders, the market seems to grow at a substantial rate during the forecast period. 

DNA Synthesis Market Segmentation Insights

The market report features a comprehensive analysis of various companies that are engaged in the global DNA synthesis industry across different segments, as defined in the table below. 

DNA Synthesis Market: Report Attributes / Market Segmentation

Key Report Attribute	Details
Historical Trend	Since 2019
Forecast Period	Till 2035
Market Size 2026	USD 1.46 Billion
Market Size 2035	USD 8.63 Billion
CAGR (Till 2035)	~22%
Method of DNA Synthesis	Chemical Method Enzymatic Method
Key Application Areas	Research & Diagnostics Therapeutic Applications
Company Size	Small  Mid-Sized Large
Key Geographical Region	North America  Europe  Asia-Pacific  Rest of the World
Key Companies Profiled	Ajinomoto Bio-Pharma Services ATUM DNA Script Eurofins Genomics Gene Universal GenScript Synbio Technologies (A full list of key companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Market Landscape Analysis Partnerships and Collaborations  Funding and Investment Analysis  Grant Analysis  Publication Analysis  Patent Analysis  Market Forecast and Future Opportunity Analysis

One of the key objectives of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunities in the DNA synthesis market over the next decade. Based on multiple parameters, such as a number of projects and service-based cost distribution, we have developed informed estimates on the evolution of the market for the forecast period till 2035. The market research report also features the likely distribution of the current and forecasted opportunity across methods of DNA synthesis (chemical method and enzymatic method), application areas (research & diagnostics and therapeutic applications), company size (small, mid-sized and large), and key geographical regions (North America, Europe and Asia-Pacific and RoW). 

To account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, portraying different tracks of the anticipated industry's growth.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market research report are in USD unless otherwise specified.

DNA Synthesis Market Share Insights

Market Share by Method of DNA Synthesis 

The DNA synthesis market report covers an in-depth analysis of the market across various method of DNA synthesis. According to our projection, chemical method accounts for the largest share of the market in the current year and is poised to hold 57% of the overall revenue share by 2035. Driven by the growing usage of enzymes for DNA isolation and synthesis, the enzymatic method is likely to grow at a higher CAGR of 21% during the forecast period. 

Market Share by Key Application Areas

Based on the key application areas, the global DNA synthesis market is distributed across research & diagnostics and therapeutic applications. Research & diagnostic applications are expected to hold 61% of the overall revenue share by 2035. This can be attributed to the extensive usage of synthetic DNA sequences in genetic engineering, molecular biology research, and synthetic biology projects. Therapeutic applications are likely to grow at a higher CAGR of 21% during the forecast period, owing to the rising interest in nucleic acid-based therapies, gene therapy, and personalized treatment.

Market Share by Company Size

The DNA synthesis market has been distributed among small, mid-sized, and large companies. Based on the company size, large companies are estimated to hold 46% of the overall revenue share. In the long run, small companies are anticipated to grow at a CAGR of 20.9% during the forecast period. 

Market Share by Key Geographical Regions 

Based on the geographical region, the DNA synthesis market is segmented across North America, Europe, Asia-Pacific, and the rest of the world. North America currently accounts for the largest share of the market and is expected to hold 50% of the overall share of the market by 2035. In Asia-Pacific and the rest of the world, the market will grow at a higher CAGR of 21% during the forecast period.

DNA Synthesis Market: Key Insights

The “DNA Synthesis Market: Industry Trends and Global, till 2035” market report features a detailed study of the current market landscape, market size, market forecast and future opportunities for the DNA synthesis technologies and service providers. Further, the market research report underlines an in-depth analysis, highlighting the capabilities of technology and service providers engaged in the market.

Competitive Landscape of DNA Synthesis Market 

Currently, the market landscape features more than 65 DNA synthesis companies offering technological platforms and services for the synthesis of DNA. Overall, the market seems fragmented highlighting small, mid-sized and large companies. Among these, 50% of the active players in this field are small companies and have been established recently. A significant investment in research and development activities has been made by key industrial players to investigate DNA as a therapeutic intervention to target various disease indications. Market players are presently undertaking various strategic initiatives for the expansion of technologies / services and focus on minimizing operational costs to offer cost-effective DNA synthesis services to their clients.

Market Drivers: Increasing Demand for Application of Synthetic DNA in Therapeutic Areas

A significant driver propelling the global DNA synthesis market is the increasing requirement for synthetic oligonucleotides such as DNA or RNA to develop therapies, including gene therapies, RNA-based therapies, and targeted therapies. The subsequent advancement in technologies such as genome editing technologies and CRISPR-Cas9 has significantly improved the capability to alter DNA with higher efficiency and precision. Synthetic genes can easily be customized to control gene expression and for response modulation according to the targeted decision indication. It is worth highlighting here that in January 2024, Casgevy™ received approval from the FDA for patients aged above 12 years. In August 2022, Zynteglo® (a gene therapy for the treatment of Beta thalassemia) received approval from the FDA for adults and children. Therapeutic treatments are able to reduce the requirement for blood transfusion in patients with Beta Thalassemia. Furthermore, the growing approval of gene-based therapies from the US FDA is driving the interest of industrial leaders to develop novel therapies using synthetic genes, which will continue to drive the market during the forecast period. 

Market Trends: Strategic Funding and Partnerships Transforming the DNA Synthesis Market 

One of the significant trends in the DNA synthesis market is strategic funding and partnership for the transformation of this industry. Driven by the increasing shift towards personalized therapies, the key players in this industry are demanding high-throughput DNA isolation technologies for creating synthetic DNA with higher precision. It is worth noting here that industrial leaders have raised nearly USD 600 million in capital investment through capital venture funding within the past few years. Nearly 62% of the total investment in this field has been raised through Venture Series C funding rounds. Furthermore, 75% of the funding instances have taken place in Europe in the past few years for accelerating the technological advancements that aid in the manipulation of synthetic DNA with higher efficiency. 

Furthermore, several players have entered into strategic partnerships and acquisition deals to support the growing demand for synthetic DNA for a wide range of applications. For instance, in January 2022, Pfizer and Codex DNA inked a strategic Early Access Partnership and Licensing Agreement to develop DNA's Novel Enzymatic DNA Synthesis Technology of Codex. The technology will be used in the production of Pfizer's mRNA-based vaccine. Further, the partnership will help in enhancing Pfizer's Biotherapies Research and Development. In August 2022, DNA Script signed partnerships with Asia-Pacific Distributors to meet the growing demand for enzymatic DNA synthesis on the same day. The ongoing partnerships between key industrial leaders are estimated to drive market opportunities during the forecast period. 

Market Challenges: Limited Elongation Challenges and Regulatory Hurdles

One of the key challenges faced by the DNA synthesis market players is limited technological efficiency for generating >300 nucleotide DNA. Sequencing errors during DNA chain elongation through chemical or enzymatic processes can create difficulty in achieving desired results. Furthermore, stringent guidelines are required for the approval of gene therapies and oligonucleotides, which further slow down the research and development process. In order to facilitate the consistent manufacturing of synthetic DNA, it is essential to overcome these challenges and adhere to the standardized guidelines provided by regulatory agencies such as the FDA. 

Market Size Analysis: North America to Hold the Largest Market Share

The global DNA synthesis market is estimated to be worth $1.46 billion in 2026. North America holds the largest share of the market, with more than 55% of the DNA synthesis companies based in this region. The market is anticipated to grow at a CAGR of 22% over the forecast period of this market report. The various factors supporting this growth have been discussed above.

Leading Companies in the DNA Synthesis Market

Examples of key leading companies actively engaged in the DNA synthesis industry (which have also been profiled in this market report; the complete list of companies is available in the full report) include Ajinomoto Bio-Pharma Services, ATUM, DNA Script, Eurofins Genomics, Gene Universal, GenScript and Synbio Technologies. This market report consists of an easily searchable excel database of all the companies providing DNA synthesis technologies and services worldwide.

DNA Synthesis Market Report Coverage

In addition to other elements, the market research report covers:

• A detailed assessment of the overall landscape of the DNA synthesis market, providing information on the type of offering, method of DNA synthesis (chemical method and enzymatic method), type of DNA molecule, custom offerings, and application area. Additionally, the report provides information on drug developer(s) involved in the market, along with analyses based on a number of relevant parameters, such as year of establishment, company size, and geographical location of headquarters.

• Elaborate profiles of the key players involved in providing technologies and services in the DNA synthesis market. Each profile features a brief overview of the company, its financial information, details on its technology / service portfolio, financial information, recent developments, and an informed future outlook.
• A detailed overview of the current market landscape of oligonucleotide manufacturers focused on research and diagnostic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).
• A detailed overview of the current market landscape of oligonucleotide manufacturers focused on therapeutic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).

• An analysis of the partnerships established between various stakeholders in the DNA synthesis market since 2017, covering product development and commercialization agreements, R&D agreements, technology licensing agreements, other licensing agreements, mergers and acquisitions, and other relevant types of deals. 
• A review of the funding and investments made in the DNA synthesis companies, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs, and subsequent offerings at various stages of development. The analysis has been done on the basis of several parameters, such as the number of funding instances, the amount invested, the type of funding, leading players and investors, and geographical analysis.
• An in-depth analysis of grants that have been awarded to various research institutes for projects related to DNA synthesis technologies and services since 2017, on the basis of important parameters, such as year of grant award, grant amount awarded, administering institute center, support period, type of grant application, grant activity code, emerging focus area, purpose of grant award, type of recent organization, popular NIH department and prominent program officers. 
• A detailed review of more than 12,000 peer-reviewed scientific articles related to research on DNA synthesis technologies, which have been published since 2017, including analysis based on parameters such as year of publication, key focus area, type of article, popular keywords, popular authors, therapeutic area, geography and key journals (in terms of number of articles published in this domain and impact factor of the journal).
• An in-depth analysis of the patents related to DNA synthesis technologies, filed / granted, based on various parameters, such as patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, and type of applicant, and leading players (by number of patents). In addition, it features a patent valuation analysis, which evaluates the qualitative and quantitative aspects of the patents.

Recent Developments in DNA Synthesis Market

Several recent developments have taken place in the field of DNA synthesis in recent years. We have outlined some of the recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends and have been outlined in our analysis.

• In January 2026, Integrated DNA Technologies (IDT) collaborated with Ansa Biotechnologies to expand IDT's synthetic biology portfolio with Ansa's enzymatic DNA synthesis platform. The partnership enables delivery of longer, complex DNA constructs with high speed, precision, and reliability for research applications globally.
• In January 2026, Integrated DNA Technologies launched a new grant program for synthetic biology startups, providing up to 100,000 base pairs of gBlocks Gene Fragments supporting early-stage R&D by supplying essential DNA raw materials.
• In October 2025, Ansa Biotechnologies secured $54.4 million in Series B funding round led by Cerberus Ventures. The funding aims to scale DNA synthesis services, expand manufacturing capacity, and enhance customer experience to meet demand in medicine and biotechnology.
• In March 2025, Syngoi Technologies collaborated with Ribbon Bio in order to advance gene therapies using synthetic DNA.
• In February 2025, GenScript launched its Life Science Research Grant Program, planning to award over 50 grants based on scientific merit for projects in gene/cell therapy, antibody discovery, vaccines, and diagnostics.